Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial.

Neurol Neuroimmunol Neuroinflamm · 2021 · PMC8054966 · PMID 33762428

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a statistical trendno p-value reported

Although the subgroup analyses only showed a statistical trend because of the small number of cases in the subgroups, it could be speculated with caution that patients with MS without relapse activity and a low cerebral lesion load could benefit from EGCG treatment.

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.